Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 21;10(Suppl 3):55-68.
doi: 10.4137/BMI.S22430. eCollection 2015.

Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors

Mark Reinwald  1 , Tobias Boch  1 , Wolf-Karsten Hofmann  1 , Dieter Buchheidt  1
Affiliations
Review

Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors

Mark Reinwald et al. Biomark Insights. .

Abstract

Infectious complications are a major cause of morbidity and mortality in patients with hemato-oncological diseases. Although disease-related immunosuppression represents one factor, aggressive treatment regimens, such as chemotherapy, stem cell transplantation, or antibody treatment, account for a large proportion of infectious side effects. With the advent of targeted therapies affecting specific kinases in malignant diseases, the outcome of patients has further improved. Nonetheless, dependent on the specific pathway targeted or off-target activity of the kinase inhibitor, therapy-associated infectious complications may occur. We review the most common and approved kinase inhibitors targeting a variety of hemato-oncological malignancies for their immunosuppressive potential and evaluate their risk of infectious side effects based on preclinical evidence and clinical data in order to raise awareness of the potential risks involved.

Keywords: BCR signaling; BCR-ABL; BRAF; EGFR; JAK; TKI; VEGF; infections; infectious complications; kinase inhibitors; mTOR; targeted therapy.

PubMed Disclaimer

References

    1. Jabbour E, Cortes J, Ravandi F, O’Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013;50:271–83. - PMC - PubMed
    1. Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75:297–308. - PubMed
    1. Daste A, Grellety T, Gross-Goupil M, Ravaud A. Protein kinase inhibitors in renal cell carcinoma. Expert Opin Pharmacother. 2014;15:337–51. - PubMed
    1. Minuti G, D’Incecco A, Landi L, Cappuzzo F. Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15:1203–13. - PubMed
    1. Dossett LA, Kudchadkar RR, Zager JS. BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf. 2015;14:559–70. - PubMed